novel
seri
indolylthiosemicarbazid
cycliz
product
design
synthes
evalu
vitro
antivir
activ
wide
rang
dna
rna
virus
compound
exhibit
notabl
antivir
activ
coxsacki
viru
ec
valu
rang
lgml
select
index
ratio
cytotox
antivir
effect
concentr
valu
compound
besid
also
inhibit
replic
two
rna
virus
sindbi
viru
respiratori
syncyti
viru
although
ec
valu
higher
compar
note
coxsacki
viru
sar
analysi
indic
keep
free
thiosemicarbazid
moieti
crucial
obtain
antivir
activ
sinc
cycliz
product
produc
antivir
effect
viral
diseas
continu
caus
seriou
morbid
mortal
worldwid
sever
viru
infect
antivir
medic
present
avail
clear
need
new
antivir
agent
new
mechan
action
broadspectrum
activ
face
issu
drugresist
mutant
virus
emerg
neglect
virus
picornavirida
famili
nonenvelop
singlestrand
rnavirus
antivir
drug
yet
avail
among
enteroviru
genu
particular
medic
import
contain
coxsacki
virus
classifi
group
serotyp
group
b
serotyp
base
earli
observ
pathogen
mice
coxsacki
viru
group
b
cvb
lesser
extent
coxsacki
viru
group
enterovirus
main
viral
caus
myocard
pericard
cvb
also
associ
wide
varieti
diseas
includ
diabet
common
cold
cardiomyopathi
neurolog
disord
inflamm
outbreak
cvb
occur
annual
throughout
world
sever
synthet
molecul
report
select
inhibitor
enterovirus
enter
clinic
trial
unfortun
neither
investig
compound
formal
approv
treatment
acut
enterovir
includ
coxsacki
viru
infect
indol
core
ubiquit
substructur
larg
number
biolog
activ
natur
synthet
molecul
delavirdin
arbidol
ii
methisazon
iii
fig
indol
deriv
market
drug
use
treat
viral
diseas
arbidol
influenza
viru
inhibitor
market
russia
china
countri
report
wide
spectrum
antivir
activ
number
envelop
nonenvelop
virus
addit
influenza
virus
instanc
arbidol
found
exhibit
potent
inhibitori
activ
anoth
indol
compound
nmethylisatinbthiosemicarbazon
methisazon
use
prevent
treatment
smallpox
base
vitro
studi
antivir
spectrum
methisazon
appear
includ
divers
dna
rna
virus
seri
investig
isatinbthiosemicarbazon
reveal
antivir
properti
variou
viru
type
herp
simplex
viru
hsv
moloney
leukemia
viru
japanes
enceph
viru
human
immunodefici
viru
hiv
recent
report
zhang
et
al
isatinbhydrazon
deriv
encod
describ
promis
antivir
agent
broad
antivir
vitro
activ
includ
report
indol
deriv
synthes
giampieri
et
al
isoindolylurea
synthes
verma
et
al
anoth
class
deriv
reveal
promis
antivir
properti
http
elsevi
ltd
right
reserv
past
decad
compound
scaffold
found
inhibit
replic
neurotrop
alphaviru
wild
type
drugresist
mutant
strain
anoth
relev
scaffold
substructur
present
sever
small
synthet
molecul
endow
vitro
antivir
characterist
view
literatur
report
focus
work
design
synthesi
new
seri
indolylthiosemicarbazid
cycliz
product
new
compound
evalu
vitro
antivir
activ
wide
varieti
dna
rna
virus
synthet
pathway
prepar
target
product
illustr
scheme
key
intermedi
previous
synthes
patent
bamaung
et
al
angiogenesi
inhibitor
structur
new
compound
establish
microanalysi
ir
h
nmr
c
nmr
proton
decoupl
apt
hsqc
hmbc
electrospray
ioniz
mass
spectrometri
esim
absolut
stereochemistri
determin
xray
diffract
studi
absenc
nah
reson
intermedi
hydrazid
ppm
togeth
three
new
reson
locat
ppm
assign
n
h
n
h
n
h
proton
support
synthesi
new
thiosemicarbazid
observ
new
lactam
c
band
cm
besid
c
amid
band
cm
ir
spectra
provid
evid
ring
closur
new
singlet
assign
methylen
proton
ring
ppm
h
nmr
spectra
provid
confirm
peak
associ
indol
subunit
observ
expect
region
assign
basi
h
f
coupl
figur
structur
indol
contain
antivir
drug
delavirdin
arbidol
ii
methisazon
iii
antivir
evalu
cellbas
assay
reveal
compound
interest
activ
coxsacki
viru
effect
observ
two
differ
cell
line
hela
vero
tabl
quit
strong
sinc
antivir
ec
valu
rang
lgml
valu
select
index
ratio
cytotox
antivir
effect
concentr
see
valu
squar
bracket
tabl
compound
ethyl
substitu
slightli
potent
analog
carri
methyl
propyl
allyl
moieti
also
visibl
doserespons
curv
shown
figur
besid
also
inhibit
replic
two
rna
virus
sindbi
viru
respiratori
syncyti
viru
although
ec
valu
higher
compar
note
coxsacki
viru
note
analog
carri
larger
butyl
aromat
substitu
r
posit
devoid
antivir
activ
crucial
role
free
thiosemicarbazid
moieti
evid
fact
cycliz
analog
produc
antivir
effect
compound
display
activ
rnavirus
test
hiv
influenza
viru
dnavirus
ie
felin
herpesviru
vaccinia
viru
tabl
hand
broad
antivir
test
allow
determin
cytotox
test
compound
divers
mammalian
cell
line
tabl
analysi
reveal
deriv
consist
less
cytotox
correspond
thiosemicarbazid
within
seri
compound
endow
anticoxsacki
viru
activ
tend
less
cytotox
antivir
inact
counterpart
effici
synthes
novel
thiosemicarbazid
deriv
scaffold
evalu
vitro
antivir
activ
broad
rang
dna
rna
virus
compound
exhibit
signific
select
inhibitori
effect
replic
coxsacki
viru
compound
also
weaker
antivir
activ
sindbi
viru
respiratori
syncyti
viru
sar
analysi
indic
keep
free
thiosemicarbazid
moieti
crucial
antivir
activ
sinc
cycliz
product
produc
antivir
effect
also
observ
presenc
bulkier
butyl
aromat
substitu
r
posit
led
dramat
decreas
biolog
activ
conclus
promis
anticoxsacki
viru
activ
new
indolylthiosemicarbazid
deriv
make
interest
lead
compound
antivir
drug
develop
henc
embark
structur
optim
besid
mechanist
antivir
experi
improv
understand
antivir
activ
solut
mol
ethanol
ml
water
ml
concd
hcl
ml
aqueou
nano
solut
ml
ad
dropwis
stir
result
solut
diazonium
salt
pour
cool
mixtur
ethyl
mol
ethanol
ml
water
ml
koh
g
stir
result
mixtur
refriger
overnight
red
oili
residu
thu
obtain
separ
wash
water
use
without
purif
solut
mol
concd
hcl
ml
heat
reflux
h
crude
product
filter
wash
water
test
neutral
litmu
use
without
purif
mixtur
mol
ethanol
ml
h
nnh
ml
heat
reflux
h
result
brown
compound
evalu
antivir
activ
cell
cultur
use
cytopath
effect
cpe
reduct
assay
broad
divers
panel
dnaand
rnavirus
human
cervix
carcinoma
hela
cell
use
studi
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
african
green
monkey
kidney
vero
cell
use
evalu
parainfluenza
viru
type
reoviru
type
sindbi
viru
coxsacki
viru
punta
toro
viru
virus
evalu
human
embryon
lung
fibroblast
cell
herp
simplex
viru
type
vaccinia
viru
vesicular
stomat
viru
madindarbi
canin
kidney
mdck
cell
use
antivir
evalu
influenza
b
virus
felin
herp
viru
felin
canin
viru
grown
crandellre
felin
kidney
cell
final
monitor
human
tlymphoblast
cell
perform
antivir
assay
virus
ad
subconflu
cultur
cell
plate
time
test
compound
ad
serial
dilut
appropri
refer
compound
includ
viral
entri
inhibitor
dextran
sulfat
mw
broad
antivir
agent
ribavirin
antiherpet
agent
ganciclovir
brivudin
hiv
inhibitor
azidothymidin
day
incub
case
influenza
viru
compound
inhibitori
effect
virusinduc
cytopath
effect
well
cytotox
monitor
light
microscopi
perform
mt
cell
viabil
assay
celltit
aq
ueou
one
solut
cell
prolifer
assay
promega
antivir
activ
express
effect
concentr
ec
wherea
cytotox
defin
minim
cytotox
concentr
base
microscopi
cc
cytotox
concentr
assess
mt
assay
